Jennifer I Lim

Has grant

Vice Chair; Marion H Schenk Chair in Ophthalmolgy, Director of Retina Service

University of Illinois at Chicago College of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Differential artery-vein analysis in OCT angiography for objective classification of diabetic retinopathy

Open Date: 2020-02-01

Close Date: 2024-01-31

Articles (19)

Year:

2026

Year:

2026

Year:

2026

Purpose: To investigate the potential utility of intravitreal antivascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR). Methods: Retrospective review of anatomical and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes. Results: There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received both bevacizumab and aflibercept). Follow-up ranged from 1 to 120 months (mean = 21 months). Within 1 month after anti-VEGF treatment, VA improved ≥2 lines in 18/45 eyes, remained stable in 26/45 eyes, and worsened in 1/45 eyes. The median visual acuity remained 20/20 for stage 3 and improved from 20/200 to 20/30 for stage 4 PSR eyes. More stage 4 PSR eyes had VA improvement posttreatment than stage 3 PSR eyes ( P = 0.003). There were no cases of endophthalmitis. Visual acuity outcomes were similar for anti-VEGF with and without laser treatment. Control of PSR was achieved in 42/45 (93%) of eyes without the need for pars plana vitrectomy. Conclusion: Within one month of treatment, administration of anti-VEGF therapy of PSR eyes resulted in seafan regression, clearing of vitreous hemorrhage, and stable or improved vision in most eyes.

Year:

2026

Year:

2025

Year:

2025

Purpose: Outcomes of sutureless scleral-fixated intraocular lens have primarily focused upon short-term results. This retrospective, observational clinical study focuses upon the long-term visual acuity and anatomic outcomes of sutureless scleral-fixated intraocular lenses. Methods: A comprehensive medical record review of patients that underwent sutureless scleral-fixated intraocular lens placement by a single surgeon from 2015 through 2024 was performed. Pre- and postoperative best-corrected visual acuity, anatomic outcomes, and complications were documented. Statistical analysis was performed. Results: Forty-three patients (ages 18–91 years, mean = 63) with follow-up ranging from 1 to 100.5 months (mean = 27.5, median = 14.67) met inclusion criteria. Mean preoperative best-corrected visual acuity was 1.11 logarithm of the minimum angle of resolution units (Snellen ratio: 20/250) ± 0.59 SD. Mean postoperative best-corrected visual acuity improvement was statistically significant at 1, 3, 6, 9 months, and 1, 2, 3 years. Postoperative complications included hyphema (n = 3), vitreous hemorrhage (n = 14), transient ocular hypertension (n = 8) and hypotony (n = 5), haptic erosion (n = 3), intraocular lens dislocation or damage (n = 4), and cystoid macular edema (n = 8). All complications were identified within 1.25 years of follow-up excluding 2 cases of cystoid macular edema. Conclusion: Sutureless scleral-fixated intraocular lens patients demonstrated statistically significant and gradual best-corrected visual acuity improvement up to 3 years postoperatively. Cases of cystoid macular edema were identified up to 3 years postoperatively.

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (14)

Fumi Gomi

Hyogo medical university

JAPAN
View details

XINCHENG YAO

Richard & Loan Hill Professor

University of Chicago

UNITED STATES
View details

Tiarnan Keenan

National Institutes of Health

UNITED STATES
View details

Cecilia Lee

Professor

University of Washington

UNITED STATES
View details

Samantha Fraser‐Bell

University of Sydney

AUSTRALIA
View details

Mojtaba Rahimi

University of Chicago

UNITED STATES
View details

Andreas Pollreisz

Associate Professor

Medical University of Vienna

AUSTRIA
View details

Aaron Lee

Assistant Professor

University of Washington

UNITED STATES
View details

Amitha Domalpally

Associate Professor

University of Wisconsin-Madison

UNITED STATES
View details

Emily Chew

NIH Distinguished Investigator

-

UNITED STATES
View details

Michael Abramoff

Staff Ophthalmologist

University of Iowa Healthcare

UNITED STATES
View details

Avni Finn

Associate Professor

Vanderbilt University School of Medicine

UNITED STATES
View details

Joel Schuman

Professor of Biomedical Engineering

Drexel University

UNITED STATES
View details

Anat Loewestein

-

ISRAEL
View details